Cargando…
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β(1) secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial
To evaluate the effect of SGLT2 inhibitor (SGLT2i) on albuminuria, nephrin (NPH) and transforming-growth-factor-beta(1) (TGF-β1) levels in urine and low-grade inflammation in type 2 diabetes (T2D) patients. A randomized, blank-controlled clinical trial included 68 T2D patients and 10 controls. Based...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489863/ https://www.ncbi.nlm.nih.gov/pubmed/36127497 http://dx.doi.org/10.1038/s41598-022-19988-7 |